Detalhe da pesquisa
1.
International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial.
BJU Int
; 133(2): 179-187, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37463104
2.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Lancet Oncol
; 24(5): 443-456, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37142371
3.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Lancet
; 399(10323): 447-460, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34953525
4.
Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(4): 501-513, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35279270
5.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411939
6.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
; 19(6): e1003998, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671327
7.
Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
Future Oncol
; 17(33): 4431-4446, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34409852
8.
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
N Engl J Med
; 377(4): 338-351, 2017 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28578639
9.
Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practice.
BMC Med Res Methodol
; 20(1): 198, 2020 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32711460
10.
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Lancet
; 392(10162): 2353-2366, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355464
11.
Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy.
Eur J Nucl Med Mol Imaging
; 46(4): 901-907, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30617554
12.
Comment on "Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients".
Br J Cancer
; 128(5): 711-712, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36717675
13.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet
; 387(10024): 1163-77, 2016 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26719232
14.
Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.
Eur J Nucl Med Mol Imaging
; 44(4): 620-629, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27770145
15.
The Role of Hypofractionated Radiotherapy in Prostate Cancer.
Curr Oncol Rep
; 19(4): 30, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28343352
16.
Symptom clusters for revising scale membership in the analysis of prostate cancer patient reported outcome measures: a secondary data analysis of the Medical Research Council RT01 trial (ISCRTN47772397).
Qual Life Res
; 26(8): 2103-2116, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28352980
17.
Intermediate clinical endpoints in localised prostate cancer.
Lancet Oncol
; 22(3): 294-296, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662281
18.
Considering benefit and risk before routinely recommending SpaceOAR.
Lancet Oncol
; 22(1): 11-13, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387489
19.
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Lancet Oncol
; 17(8): 1047-1060, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27339115
20.
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.
Br J Cancer
; 114(10): 1165-74, 2016 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27070714